基石药业-B（股票代码：02616）于2026年5月7日发布2026年4月股份变动月报。公告显示，公司截至本月末的注册股本仍为2,000,000,000股、面值0.0001美元，法定股本为200,000美元，均与上月保持不变。
根据月报披露信息，4月末已发行股份（不含库存股）由上月底的1,476,018,722股上升至1,600,249,187股，当月累计新增124,230,465股。此次新增股份主要来自两部分：其一，公司在4月22日以每股8.97港元的价格完成118,000,000股配售；其二，根据公司首发后限制性股份奖励计划，于4月23日实际发行6,000,000股。期权与激励计划方面，首次公开募股（IPO）前激励计划有13,332股期权行使，IPO后员工持股计划中行使217,133股期权并失效41,151股期权。本月因行使期权共募集资金670,941.88港元。截至月末，公司库存股份数为0股，未发生购回或注销行为。
公司确认其已充分符合香港联交所相关上市规则、法律及监管要求，并表示上述股份发行及期权行使均经董事会正式授权和批准。公告由董事李伟签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.